BRIEF-E I L Holdings Ltd Files To Withdraw U.S. IPO Plans-February 2024-www.financetom.com

BRIEF-E I L Holdings Ltd Files To Withdraw U.S. IPO Plans

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-E I L Holdings Ltd Files To Withdraw U.S. IPO Plans

Jun 24, 2025 6:26 AM

June 24 (Reuters) - E I L Holdings Ltd:

* E I L HOLDINGS LTD FILES TO WITHDRAW U.S. IPO PLANS - SEC

FILING

* E I L HOLDINGS LTD SAYS IT HAD FILED FOR U.S. IPO IN

DECEMBER

2023

Further company coverage:

Previous page： Next page： Ford's first-quarter US auto sales rise 6.8%

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Apr 3, 2024

...

Ford's first-quarter US auto sales rise 6.8%

Apr 3, 2024

April 3 (Reuters) - Ford Motor Co ( F ) reported a 6.8% rise in first-quarter U.S. auto sales, driven by demand for its F-series pickup trucks and crossover SUVs. The Detroit automaker notched sales of 508,083, compared with 475,906 a year earlier. (Reporting by Nathan Gomes in Bengaluru; Editing by Sriraj Kalluvila) ...

Microsoft, Quantinuum claim breakthrough in quantum computing

Apr 3, 2024

(Reuters) - Microsoft ( MSFT ) and Quantinuum on Wednesday said they have achieved a key step in making quantum computers a commercial reality by making them more reliable. The move is the latest in a race to perfect quantum computing in which tech firms such as Microsoft ( MSFT ), Alphabet's Google and IBM ( IBM ) are jostling...

Why Kintara Therapeutics Shares Are Gaining Today

Apr 3, 2024

Kintara Therapeutics, Inc. ( KTRA ) shares are trading higher in the premarket session on Wednesday with heavy volume. The company entered into a definitive merger agreement with TuHURA Biosciences. The combined company will focus on advancing TuHURA’s personalized cancer vaccines and bi-functional ADCS. These two technologies seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer....